Abstract
SEPT9 is a mammalian septin family member. There is growing evidence that SEPT9 plays a role in cancer. The protein product, SEPT9_V1, associates with microtubules and interacts with hypoxia-inducible factor (HIF)-1α, the regulated subunit of the key transcription factor HIF-1. HIF-1 transcriptional activity is thoroughly dependent on intact microtubules. We tested the hypothesis that SEPT9_V1 confers resistance to microtubule-mediated HIF-1 inhibitors. SEPT9_V1 protein expression was strongly correlated with susceptibility of a wide range of cancer cells to 2-methoxyestradiol and paclitaxel. Our results revealed that SEPT9_V1 could serve as a biomarker for therapeutic resistance to microtubule disrupting agents. ©2007 Landes Bioscience.
Author supplied keywords
Cite
CITATION STYLE
Amir, S., & Mabjeesh, N. J. (2007). SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule disrupting agents. Cancer Biology and Therapy, 6(12), 1926–1931. https://doi.org/10.4161/cbt.6.12.4971
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.